Lymphoma, B-Cell
Oncology·MeSH: Lymphoma, B-Cell
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
4 drugs in development·3 companies·7 clinical trials
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| FT819 | FATE THERAPEUTICS INC (FATE) |
Phase 1(1)
| Drug | Company |
|---|---|
| IL-2 | FATE THERAPEUTICS INC (FATE) |
Phase 1/Phase 2(2)
Compare drugs
Frequently asked questions
How many drugs are in development for Lymphoma, B-Cell?
BioSniper tracks 4 drugs in development for Lymphoma, B-Cell across 3 companies.
How many clinical trials target Lymphoma, B-Cell?
There are 7 clinical trials targeting Lymphoma, B-Cell tracked by BioSniper.
What is the prevalence of Lymphoma, B-Cell?
The estimated prevalence of Lymphoma, B-Cell is approximately 56.0 per 100,000 population.
Deep-dive into Lymphoma, B-Cell
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis